Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.

Barron JL, Coy DH, Millar RP

Peptides1 May 1985Cited by 12 (Europe PMC)

PMID2866496DOI10.1016/0196-9781(85)90124-xPepBankPUB-02866496

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In five normal men, GHRH(1-29)-NH2 increased the integrated plasma GH response at each dose tested.
In plain wordsIn five healthy men, the GHRH peptide raised growth hormone at every dose tested.
Peptide
Sermorelin
Outcome
IncreaseIntegrated plasma GH response
Study
n = 5
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.015 to 0.5 micrograms/kg body weight · intravenous bolusAs given in this study (human).
Source sentences
Summary
An increase in the integrated plasma growth hormone (GH) response was observed at each dose.
1 context sentence(design, population, supporting numbers)
Summary · context
Synthetic analogs of growth hormone-releasing hormone, GHRH(1-29)-NH2 and D-Ala2 GHRH(1-29)-NH2 were administered as a bolus intravenous injection to five normal men in a dose range of 0.015 to 0.5 micrograms/kg body weight.
Report a problemFND-0286649601
02HumanNon-randomized trialEfficacy outcome
In five normal men, peak GH responses to GHRH(1-29)-NH2 occurred at 15 or 30 minutes.
In plain wordsIn five healthy men, growth hormone peaked 15 to 30 minutes after the GHRH peptide.
Peptide
Sermorelin
Outcome
Not applicableTime of peak GH response
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.015 to 0.5 micrograms/kg body weight · intravenous bolusAs given in this study (human).
Measurements
Time to peak GH response
15 to 30 min
GHRH analogs
Source sentences
Summary
Peak responses to GHRH analogs occurred at 15 or 30 min.
1 context sentence(design, population, supporting numbers)
Summary · context
Synthetic analogs of growth hormone-releasing hormone, GHRH(1-29)-NH2 and D-Ala2 GHRH(1-29)-NH2 were administered as a bolus intravenous injection to five normal men in a dose range of 0.015 to 0.5 micrograms/kg body weight.
Report a problemFND-0286649602
03HumanNon-randomized trialEfficacy outcome
In five normal men, GHRH(1-29)-NH2 had a molar potency similar to GHRH(1-40) and GHRH(1-44).
In plain wordsIn five healthy men, the short GHRH peptide was about as strong as the longer natural forms.
Peptide
Sermorelin
Outcome
No significant changePotency of GHRH(1-29)-NH2 versus GHRH(1-40) and GHRH(1-44)
Study
n = 5
Comparator
GHRH(1-40) and GHRH(1-44)
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.015 to 0.5 micrograms/kg body weight · intravenous bolusAs given in this study (human).
Source sentences
Summary
The dose-response curve of GHRH(1-29)-NH2 indicated that it has a similar molar potency to GHRH(1-40) and GHRH(1-44).
1 context sentence(design, population, supporting numbers)
Summary · context
Synthetic analogs of growth hormone-releasing hormone, GHRH(1-29)-NH2 and D-Ala2 GHRH(1-29)-NH2 were administered as a bolus intravenous injection to five normal men in a dose range of 0.015 to 0.5 micrograms/kg body weight.
Report a problemFND-0286649603
04HumanNon-randomized trialEfficacy outcome
In five normal men, neither GHRH(1-29)-NH2 nor its D-Ala2 analog changed blood levels of PRL, TSH, LH, FSH, ACTH, insulin, glucagon, glucose, cortisol, free thyroxine or free triiodothyronine.
In plain wordsIn five healthy men, the GHRH peptide did not change blood levels of other hormones or glucose.
Peptide
Sermorelin
Outcome
No significant changeOther hormones, glucose and metabolites after GHRH(1-29)-NH2
Study
n = 5
Comparator
Vehicle
Outcome group
Pituitary hormones · Endocrine and hormones
Studied dose
0.015 to 0.5 micrograms/kg body weight · intravenous bolusAs given in this study (human).
Source sentences
Summary
Neither analog affected blood levels of PRL, TSH, LH, FSH, ACTH, insulin, glucagon, glucose, cortisol, free thyroxine, and free triiodothyronine.
1 context sentence(design, population, supporting numbers)
Summary · context
Synthetic analogs of growth hormone-releasing hormone, GHRH(1-29)-NH2 and D-Ala2 GHRH(1-29)-NH2 were administered as a bolus intravenous injection to five normal men in a dose range of 0.015 to 0.5 micrograms/kg body weight.
Report a problemFND-0286649604
05HumanNon-randomized trialSafety outcome
In five normal men, the only side effect noted was transient flushing at the highest dose.
In plain wordsIn five healthy men, the only side effect was short flushing at the highest dose.
Peptide
Sermorelin
Outcome
Not applicableSide effects of GHRH(1-29)-NH2
Study
n = 5
Outcome group
Adverse events · Endocrine and hormones
Studied dose
0.015 to 0.5 micrograms/kg body weight · intravenous bolusAs given in this study (human).
Source sentences
Summary
No side effects were noted other than transient flushing with the highest dose administered.
1 context sentence(design, population, supporting numbers)
Summary · context
Synthetic analogs of growth hormone-releasing hormone, GHRH(1-29)-NH2 and D-Ala2 GHRH(1-29)-NH2 were administered as a bolus intravenous injection to five normal men in a dose range of 0.015 to 0.5 micrograms/kg body weight.
Report a problemFND-0286649605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.